GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2019 Epidiolex U.S. Q1 net sales of $33.5m  Positive Phase 3 pivotal results...

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome – Primary endpoint achieved with both EPIDIOLEX doses compared...